ANA Therapeutics, a Silicon Valley-based biotech startup, and Quotient Sciences, a provider of drug development and manufacturing solutions, are partnering to support the manufacturing of ANA Therapeutics’ drug candidate, ANA001 (niclosamide capsules), which they are developing as a potential treatment for COVID-19. As part of the collaboration, Quotient will scale up the capsule formulation, characterize and optimize the manufacturing process and ensure continuity of drug product through clinic...